Evidence map›Paper›PMID 33707599›Full record

ArticleScientific reports2021

Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia with kinase fusions in Taiwan.

Yin-Chen Hsu, Chih-Hsiang Yu, Yan-Ming Chen, Kathryn G Roberts, Yu-Ling Ni, Kai-Hsin Lin, Shiann-Tarng Jou, Meng-Yao Lu, Shu-Huey Chen, Kang-Hsi Wu and 10 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. LowFrontiers in medicine · 2025
    Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 2 countries.

Yin-Chen Hsu *Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, No. 1, Changde Street, Zhongzheng District 10048, Taipei, Taiwan.
Chih-Hsiang Yu *Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, No. 1, Changde Street, Zhongzheng District 10048, Taipei, Taiwan.
Yan-Ming ChenDepartment of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, No. 1, Changde Street, Zhongzheng District 10048, Taipei, Taiwan.
Kathryn G RobertsDepartment of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105-3678, USA.
Yu-Ling NiDepartment of Laboratory Medicine, National Taiwan University Hospital, 100, No 7, Chung Shan South Road, Taipei, Taiwan.
Kai-Hsin LinDepartment of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.
Shiann-Tarng JouDepartment of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.
Meng-Yao LuDepartment of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.
Shu-Huey ChenDepartment of Pediatrics, Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan.
Kang-Hsi WuDepartment of Pediatrics, Chung Shan Medical University Hospital and School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Hsiu-Hao ChangDepartment of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.
Dong-Tsamn LinDepartment of Laboratory Medicine, National Taiwan University Hospital, 100, No 7, Chung Shan South Road, Taipei, Taiwan.
Shu-Wha LinDepartment of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, No. 1, Changde Street, Zhongzheng District 10048, Taipei, Taiwan.
Ze-Shiang LinDepartment of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, No. 1, Changde Street, Zhongzheng District 10048, Taipei, Taiwan.
Wei-Tzu ChiuDepartment of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, No. 1, Changde Street, Zhongzheng District 10048, Taipei, Taiwan.
Chia-Ching ChangDepartment of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, No. 1, Changde Street, Zhongzheng District 10048, Taipei, Taiwan.
Bing-Ching HoCenters of Genomic and Precision Medicine, National Taiwan University, Taipei, Taiwan.
Charles G MullighanDepartment of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105-3678, USA. charles.mullighan@stjude.org.
Sung-Liang YuDepartment of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, No. 1, Changde Street, Zhongzheng District 10048, Taipei, Taiwan. slyu@ntu.edu.tw.
Yung-Li YangDepartment of Laboratory Medicine, National Taiwan University Hospital, 100, No 7, Chung Shan South Road, Taipei, Taiwan. yangyl92@ntu.edu.tw.
National Taiwan University · TWNational Taiwan University Hospital · TWSt. Jude Children's Research Hospital · USChung Shan Medical University Hospital · TWTaipei Medical University-Shuang Ho Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukaemia (ALL), a high-risk subtype characterised by genomic alterations that activate cytokine receptor and kinase signalling, is associated with inferior outcomes in most childhood ALL clinical trials. Half of the patients with Ph-like ALL have kinase rearrangements or fusions. We examined the frequency and spectrum of these fusions using a retrospective cohort of 212 newly diagnosed patients with childhood B-cell ALL. Samples without known chromosomal alterations were subject to multiplex reverse transcription polymerase chain reaction to identify known Ph-like kinase fusions. Immunoglobulin heavy chain locus (IGH) capture and kinase capture were applied to samples without known kinase fusions. We detected known kinase fusions in five of 212 patients, comprising EBF1-PDGFRB, ETV6-ABL1, ZC3HAV1-ABL2, EPOR-IGH, and CNTRL-ABL1. Two patients with P2RY8-CRLF2 were identified. Patients with non-Ph kinase fusions had inferior 5-year event-free survival and overall survival compared with patients with other common genetic alterations. The prevalence of non-Ph kinase fusions in our Taiwanese cohort was lower than that reported in Caucasian populations. Future clinical trials with tyrosine kinase inhibitors may be indicated in Taiwan because of the inferior outcomes for B-cell ALL with kinase fusions.

Indexed as

Philadelphia ChromosomeBase SequenceChildChild, PreschoolCohort StudiesFemaleGene DeletionGene RearrangementHumansImmunoglobulin Heavy ChainsInfantMaleNeoplasm ProteinsOncogene Proteins, FusionPrecursor B-Cell Lymphoblastic Leukemia-LymphomaProgression-Free SurvivalImmunoglobulin Heavy ChainsNeoplasm ProteinsOncogene Proteins, FusionProtein Kinases

Identifiers

PMID33707599
PMCPMC7952704
OpenAlexW3135549399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.